Cardiff Oncology Inc SEC Filings

Cardiff Oncology reported first quarter 2026 results and a major clinical and leadership update. The company posted a net loss attributable to common stockholders of $12.4 million, or $0.18 per share, compared with a loss of $13.4 million, or $0.20 per share, a year earlier. Total operating expenses fell to $12.9 million from $14.5 million as research and development spending declined, partly offset by higher selling, general and administrative costs tied to severance and stock‑based compensation. Cash, cash equivalents and short‑term investments totaled $46.1 million as of March 31, 2026, and the company expects this to fund operations into the first quarter of 2027.

Clinically, Cardiff highlighted positive randomized Phase 2 CRDF‑004 data in first‑line RAS‑mutated metastatic colorectal cancer, where the 30 mg onvansertib plus FOLFIRI/bevacizumab arm achieved a confirmed objective response rate of 72.2% versus 43.2% across combined standard‑of‑care arms and showed improved progression‑free survival (hazard ratios 0.38 and 0.37, p<0.05) without significant added toxicity. Following a successful End‑of‑Phase 2 FDA meeting, the company selected a 30 mg onvansertib dose with FOLFIRI/bev for a planned Phase 3 registrational trial and plans to share more details by mid‑2026. Cardiff also announced that updated CRDF‑004 data will be presented in a rapid oral session at the 2026 ASCO Annual Meeting and that new preclinical data support combining onvansertib with an antibody‑drug conjugate in HER2‑low breast cancer models. Leadership was strengthened with Mani Mohindru appointed permanent CEO and new CFO and COO hires to support upcoming clinical and regulatory milestones.

Cardiff Oncology reported a net loss of $12.3 million for the quarter ended March 31, 2026, on royalty revenue of just $41,000. Operating expenses were $12.9 million, with research and development down to $6.8 million and selling, general and administrative expenses up to $6.1 million, largely from severance and stock-based compensation.

The company ended the quarter with $46.1 million in cash, cash equivalents and short‑term investments and used $12.3 million in operating cash, and management concluded there is substantial doubt about its ability to continue as a going concern beyond the next 12 months without new financing. Cardiff advanced its lead PLK1 inhibitor onvansertib, highlighting strong Phase 2 data in first‑line RAS‑mutated metastatic colorectal cancer and alignment with the FDA on a Phase 3 design, but also disclosed a license dispute with Nerviano that could, if unresolved, lead to termination of the onvansertib license and materially harm the business.

Cardiff Oncology Chief Operating Officer Ajay Aggarwal received a grant of stock options covering 400,000 shares of common stock. The options have an exercise price of $1.72 per share and expire on April 27, 2036, giving him a long-term incentive tied to the company’s share price.

According to the vesting schedule, 100,000 options vest on April 27, 2027, and 8,333 options vest monthly for 36 months beginning on May 27, 2027. After this grant, Aggarwal holds 400,000 stock options directly under this award.

Cardiff Oncology, Inc. Chief Operating Officer Ajay Aggarwal has filed an initial statement of beneficial ownership on Form 3. The filing reports no buy, sell, or other equity transactions and shows no derivative positions, serving as a baseline disclosure of his insider status.

Cardiff Oncology is asking stockholders to vote at its June 11, 2026 annual meeting on four main items: electing six directors, ratifying BDO USA as auditor, expanding the 2021 Omnibus Equity Incentive Plan, and approving executive pay on an advisory basis.

The equity plan share reserve would increase by 3,000,000 shares, bringing total issuable shares to 15,150,000, compared with 68,369,896 common shares outstanding as of April 20, 2026. The company highlights recent equity burn and overhang levels and positions the request as competitive within life sciences peers.

Cardiff Oncology, Inc. Chief Financial Officer Joshua B. Muntner filed an initial statement of beneficial ownership, reporting direct holdings of 500 shares of Common Stock. This Form 3 reflects his existing ownership position and does not show any reported purchases, sales, or option exercises.

Cardiff Oncology, Inc. reported that Chief Financial Officer Joshua B. Muntner received a grant of 486,650 stock options to purchase common stock at an exercise price of $1.58 per share. These options expire on April 6, 2036 and are held directly.

According to the vesting schedule, 121,663 options vest on April 6, 2027, and 10,139 options vest monthly for 36 months after that date. Following this award, Muntner holds a total of 487,150 stock options linked to Cardiff Oncology common stock.

Cardiff Oncology’s Chief Scientific Officer, Tod Smeal, received a grant of stock options covering 300,000 shares of common stock at an exercise price of $1.63 per share. These options were awarded as compensation, not purchased in the open market, and expire on April 14, 2036.

Following this grant, Smeal holds stock options for 1,279,805 shares in total. The award vests over time: 75,000 options vest on April 14, 2027, and 6,250 options vest monthly for 36 months thereafter, creating a multi‑year retention and incentive structure.